IL-2 Regulates Expression of C-MAF in Human CD4 T Cells

Rani, A., Afzali, B., Kelly, A., Tewolde-Berhan, L., Hacket, M., Kanhere, A., Pedroza-Pacheco, I., Bowen, H., Jurcevic, S., Jenner, R., Cousins, D., Ragheb, J., Lavender, P. and John, S. 2011. IL-2 Regulates Expression of C-MAF in Human CD4 T Cells. Journal of Immunology. 187 (7), pp. 3721-3729. https://doi.org/10.4049/jimmunol.1002354

TitleIL-2 Regulates Expression of C-MAF in Human CD4 T Cells
TypeJournal article
AuthorsRani, A., Afzali, B., Kelly, A., Tewolde-Berhan, L., Hacket, M., Kanhere, A., Pedroza-Pacheco, I., Bowen, H., Jurcevic, S., Jenner, R., Cousins, D., Ragheb, J., Lavender, P. and John, S.
Abstract

Blockade of IL-2R with humanized anti-CD25 Abs, such as daclizumab, inhibits Th2 responses in human T cells. Recent murine studies have shown that IL-2 also plays a significant role in regulating Th2 cell differentiation by activated STAT5. To explore the role of activated STAT5 in the Th2 differentiation of primary human T cells, we studied the mechanisms underlying IL-2 regulation of C-MAF expression. Chromatin immunoprecipitation studies revealed that IL-2 induced STAT5 binding to specific sites in the C-MAF promoter. These sites corresponded to regions enriched for markers of chromatin architectural features in both resting CD4 and differentiated Th2 cells. Unlike IL-6, IL-2 induced C-MAF expression in CD4 T cells with or without prior TCR stimulation. TCR-induced C-MAF expression was significantly inhibited by treatment with daclizumab or a JAK3 inhibitor, R333. Furthermore, IL-2 and IL-6 synergistically induced C-MAF expression in TCR-activated T cells, suggesting functional cooperation between these cytokines. Finally, both TCR-induced early IL4 mRNA expression and IL-4 cytokine expression in differentiated Th2 cells were significantly inhibited by IL-2R blockade. Thus, our findings demonstrate the importance of IL-2 in Th2 differentiation in human T cells and support the notion that IL-2R–directed therapies may have utility in the treatment of allergic disorders.

JournalJournal of Immunology
Journal citation187 (7), pp. 3721-3729
ISSN1550-6606
Year2011
PublisherAmerican Association of Immunologists
Accepted author manuscript
Digital Object Identifier (DOI)https://doi.org/10.4049/jimmunol.1002354
Publication dates
Published20 Sep 2011
FunderWellcome Trust
MRC (Medical Research Council)

Related outputs

Prostate Cancer: The role of inflammation and chemokines
Rani, A., Dasgupta, P. and Murphy, J.J. 2019. Prostate Cancer: The role of inflammation and chemokines. American Journal of Pathology. 189 (11), pp. 2119-2137. https://doi.org/10.1016/j.ajpath.2019.07.007

Endocrine Resistance in Hormone Receptor Positive Breast Cancer–From Mechanism to Therapy
Rani, A., Stebbing, J., Giamas, G. and Murphy, J.J. 2019. Endocrine Resistance in Hormone Receptor Positive Breast Cancer–From Mechanism to Therapy. Frontiers in Endocrinology. 10 245. https://doi.org/10.3389/fendo.2019.00245

Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer
Ribas, R., Pancholi, S., Rani, A., Schuster, E., Guest, S., Nikitorowicz-Buniak, J., Simigdala, N., Thornhill, A., Avogadri-Connors, F., Cutler, R., Lalani, A., Dowsett, M., Johnston, S. and Martin, L. 2018. Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer. Breast Cancer Research. 20, p. 44 44. https://doi.org/10.1186/S13058-018-0983-1

HES1 in immunity and cancer
Rani, A., Greenlaw, R., Smith, R.A. and Galustian, C. 2016. HES1 in immunity and cancer. Cytokine & Growth Factor Reviews. 30, pp. 113-117. https://doi.org/10.1016/j.cytogfr.2016.03.010

STAT5 in Cancer and Immunity
Murphy, J.J. and Rani, A. 2016. STAT5 in Cancer and Immunity. Journal of Interferon & Cytokine Research. 36 (4), pp. 226-237. https://doi.org/10.1089/jir.2015.0054

Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancer
López-Knowles, E., Wilkerson, P., Ribas, R., Anderson, H., Mackay, A., Ghazoui, Z., Rani, A., Osin, P., Nerurkar, A., Renshaw, L., Larionov, A., Miller, W., Dixon, J., Reis-Filho, J., Dunbier, A., Martin, L. and Dowsett, M. 2015. Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancer. Breast Cancer Research. 17, p. 35 35. https://doi.org/10.1186/S13058-015-0532-0

The Notch target Hes1, is a STAT5 target gene with implications in cancer
Rani, A., Greenlaw, R., Galustian, C. and Murphy, J.J. 2015. The Notch target Hes1, is a STAT5 target gene with implications in cancer. 2015 Meeting of the ICIS in Bamberg, Germany, October 11th -14th. Bamberg, Germany Oct 2015 https://doi.org/10.1016/j.cyto.2015.08.214

Identification of chemokine receptors as potential modulators of endocrine resistance in oestrogen receptor–positive breast cancers
Ribas, R., Ghazoui, Z., Gao, Q., Pancholi, S., Rani, A., Dunbier, A., Dowsett, M. and Martin, L. 2014. Identification of chemokine receptors as potential modulators of endocrine resistance in oestrogen receptor–positive breast cancers. Breast Cancer Research. 16, p. 447 447. https://doi.org/10.1186/s13058-014-0447-1

Permalink - https://westminsterresearch.westminster.ac.uk/item/qv871/il-2-regulates-expression-of-c-maf-in-human-cd4-t-cells


Share this

Usage statistics

96 total views
64 total downloads
These values cover views and downloads from WestminsterResearch and are for the period from September 2nd 2018, when this repository was created.